These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38745886)

  • 1. Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
    Rodriguez LA; Finertie H; Neugebauer RS; Gosiker B; Thomas TW; Karter AJ; Gilliam LK; Oshiro C; An J; Simonson G; Cassidy-Bushrow AE; Dombrowski S; Nolan M; O'Connor PJ; Schmittdiel JA
    Lancet Reg Health Am; 2024 Jun; 34():100759. PubMed ID: 38745886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System.
    Lamprea-Montealegre JA; Madden E; Tummalapalli SL; Peralta C; Neilands TB; Garcia PK; Muiru A; Karliner L; Shlipak MG; Estrella MM
    JAMA; 2022 Sep; 328(9):861-871. PubMed ID: 36066519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice.
    Nanna MG; Kolkailah AA; Page C; Peterson ED; Navar AM
    JAMA Cardiol; 2023 Jan; 8(1):89-95. PubMed ID: 36322056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis.
    Diallo A; Carlos-Bolumbu M; Galtier F
    EClinicalMedicine; 2022 Dec; 54():101697. PubMed ID: 36263397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial, ethnic and regional differences in the effect of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Kunutsor SK; Khunti K; Seidu S
    J R Soc Med; 2024 Aug; 117(8):267-283. PubMed ID: 37734450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US.
    Eberly LA; Yang L; Essien UR; Eneanya ND; Julien HM; Luo J; Nathan AS; Khatana SAM; Dayoub EJ; Fanaroff AC; Giri J; Groeneveld PW; Adusumalli S
    JAMA Health Forum; 2021 Dec; 2(12):e214182. PubMed ID: 35977298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study.
    Anson M; Zhao SS; Austin P; Ibarburu GH; Malik RA; Alam U
    Diabetologia; 2023 Oct; 66(10):1869-1881. PubMed ID: 37505282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study.
    Hao R; Myroniuk T; McGuckin T; Manca D; Campbell-Scherer D; Lau D; Yeung RO
    BMC Prim Care; 2022 May; 23(1):124. PubMed ID: 35606699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes.
    Luo J; Gabriel N; Korytkowski M; Hernandez I; Gellad WF
    Diabetes Res Clin Pract; 2022 May; 187():109855. PubMed ID: 35346753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on cardiovascular and kidney outcomes in Asian versus White patients with type 2 diabetes mellitus.
    Zhang J; Van Spall HG; Li L; Khan MS; Pandey A; Thabane L; Bai X; Wang Y; Lip GY; Li G
    Diabetes Metab Syndr; 2023 Jul; 17(7):102804. PubMed ID: 37315473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM.
    McKee A; Al-Khazaali A; Albert SG
    J Endocr Soc; 2020 May; 4(5):bvaa037. PubMed ID: 32342023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. State Variation in Racial and Ethnic Disparities in Incidence of Triple-Negative Breast Cancer Among US Women.
    Sung H; Wiese D; Jatoi I; Jemal A
    JAMA Oncol; 2023 May; 9(5):700-704. PubMed ID: 36862439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis.
    Diallo A; Carlos-Bolumbu M; Galtier F
    Acta Diabetol; 2023 Dec; 60(12):1651-1662. PubMed ID: 37439858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020.
    Adhikari R; Jha K; Dardari Z; Heyward J; Blumenthal RS; Eckel RH; Alexander GC; Blaha MJ
    J Am Heart Assoc; 2022 May; 11(9):e023811. PubMed ID: 35475341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.
    Zhang Y; Jiang L; Wang J; Wang T; Chien C; Huang W; Fu X; Xiao Y; Fu Q; Wang S; Zhao J
    Cardiovasc Diabetol; 2022 Nov; 21(1):232. PubMed ID: 36335326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low Use of Guideline-recommended Cardiorenal Protective Antihyperglycemic Agents in Primary Care: A Cross-sectional Study of Adults With Type 2 Diabetes.
    Marasinghe DH; Butalia S; Garies S; Drummond N; Kim JW; Senior PA
    Can J Diabetes; 2022 Jul; 46(5):487-494. PubMed ID: 35739042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes.
    Varshney N; Billups SJ; Saseen JJ; Fixen CW
    Ther Adv Drug Saf; 2021; 12():2042098621997703. PubMed ID: 33854754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States.
    Zhao JZ; Weinhandl ED; Carlson AM; St Peter WL
    Kidney Med; 2023 Jan; 5(1):100564. PubMed ID: 36593878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY
    Prázný M; Suplotova L; Gumprecht J; Kamenov Z; Fülöp T; Medvedchikov A; Rosenzweig D; Aleksandric M
    Cardiovasc Diabetol; 2022 Oct; 21(1):203. PubMed ID: 36209118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.
    Li J; Albajrami O; Zhuo M; Hawley CE; Paik JM
    Clin J Am Soc Nephrol; 2020 Nov; 15(11):1678-1688. PubMed ID: 32518100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.